Rybelsus: The Only Oral GLP-1 Medication

Rybelsus contains oral semaglutide co-formulated with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), an absorption enhancer that protects semaglutide from degradation in the stomach and facilitates its absorption across the gastric mucosa. Once absorbed, it works identically to injectable semaglutide: activating GLP-1 receptors to enhance insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite through central nervous system effects.

Rybelsus is the first and only oral GLP-1 receptor agonist, approved by the FDA in September 2019 for type 2 diabetes. It contains semaglutide (the same active ingredient as Ozempic and Wegovy) combined with an absorption enhancer called SNAC that allows the peptide drug to survive the stomach and be absorbed through the gastric lining. This was a significant pharmaceutical achievement, as GLP-1 peptides were previously thought to be too fragile for oral delivery. Rybelsus comes in 3 mg, 7 mg, and 14 mg tablets.

Proper administration of Rybelsus is critical for it to work. The tablet must be taken on an empty stomach first thing in the morning with no more than 4 ounces (120 mL) of plain water. Patients must then wait at least 30 minutes before eating, drinking anything else, or taking other oral medications. This fasting requirement is essential because food, beverages, and other medications in the stomach significantly reduce semaglutide absorption. The tablet should be swallowed whole and not split, crushed, or chewed. Non-adherence to these instructions is one of the most common reasons for suboptimal response to Rybelsus.

• Take first thing in the morning on a completely empty stomach
• Swallow whole with no more than 4 oz (half a glass) of plain water
• Wait at least 30 minutes before eating, drinking, or taking other medications
• Do not split, crush, or chew the tablet
• Take at least 30 minutes before any other oral medications, including thyroid medications

The PIONEER program was one of the largest Phase 3 programs for an oral diabetes medication, spanning 10 trials with over 9,500 participants. Across the program, Rybelsus 14 mg consistently demonstrated superior or non-inferior HbA1c reduction compared to placebo, empagliflozin, sitagliptin, and liraglutide. Weight loss was a consistent secondary benefit, typically 3-5 kg over 26-52 weeks at the 14 mg dose. PIONEER 6 was the cardiovascular safety trial, which showed non-inferiority to placebo for MACE. While effective, the weight loss with Rybelsus 14 mg is less than what is achieved with injectable semaglutide due to lower bioavailability of the oral formulation.

Rybelsus and Ozempic both contain semaglutide but have different pharmacokinetics due to the route of administration. Oral semaglutide has approximately 1% bioavailability, meaning only about 1% of the ingested drug reaches the bloodstream. To compensate, oral doses are much higher in absolute terms (14 mg oral vs 1 mg injectable), but the actual systemic exposure at therapeutic doses is roughly equivalent. In practice, Ozempic tends to produce slightly more weight loss and glycemic improvement than Rybelsus because injectable delivery ensures consistent bioavailability. The PIONEER 9 head-to-head trial (conducted in Japan) showed comparable efficacy between oral semaglutide 14 mg and injectable semaglutide 1 mg.

Novo Nordisk is developing a higher-dose oral semaglutide (25 mg and 50 mg) specifically for weight management. The OASIS 1 trial showed that oral semaglutide 50 mg produced 15.1% weight loss over 68 weeks, approaching the results seen with injectable Wegovy (14.9% in STEP 1). If approved, this could offer a needle-free alternative for weight management. Other pharmaceutical companies are also pursuing oral incretin therapies, including orforglipron (Eli Lilly), a non-peptide oral GLP-1 agonist that does not require fasting before administration.